You are here

Press Release Archive

 
- Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation

Pfizer Inc. (NYSE:PFE) today announced that it has received . . .

 
- Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting

Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts...

 
- Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that 13 avelumab* abstracts across seven challenging tumor types will be featured at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6, 2017 in Chicago, IL. Key presentations include data for avelumab in first-line metastatic Merkel cell carcinoma (mMCC) and in previously treated metastatic urothelial carcinoma (UC), as well as results from the Phase Ib trial investigating avelumab in combination with the tyrosine kinase inhibitor axitinib, in advanced renal cell carcinoma (RCC).

 
- SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced... 

 
- FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer...

 
- FDA Grants Second Approval for BAVENCIO® (avelumab)

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announce that the US Food and Drug Administration (FDA) has granted accelerated approval for BAVENCIO® (avelumab) Injection for a second indication. The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

 
- New Smartphone App May Enable Lupus Patients to Report Symptoms More Easily and Accurately

The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test a custom smartphone app enabling lupus patients to report on their fatigue and other symptoms in real time. Incorporating feedback from people with lupus, the new app will be evaluated through a non-interventional clinical study called VALUE (VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool), scheduled to begin at the end of this month.

 
- Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the World’s Poorest Countries

Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.

 
- Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine

Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine (NEJM).

 
- Pfizer Reports First-Quarter 2017 Results

Please find Pfizer’s press release and associated financial tables at the following hyperlink: Pfizer Reports First-Quarter 2017 Results

 
- Pfizer Hosts Annual Meeting of Shareholders

The board of directors of Pfizer Inc. today declared a 32-cent second-quarter 2017 dividend on the company’s common stock, payable June 1, 2017, to shareholders of record at the close of business on May 12, 2017. The second-quarter 2017 cash dividend will be the 314th consecutive quarterly dividend paid by Pfizer.

 
- Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), previously treated with one or more ALK inhibitors.

 
- Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries

Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.